Ibio Inc (IBIO)
$1.81
0.00 (0.00%)
IBIO Stock Quote Delayed 30 Minutes
Previous Close
-
Market Cap
28.85M
PE Ratio
-1.06
EPS
-1.7
Volume (Avg. Vol.)
387
Day's Range
1.81 - 1.81
52-Week Range
0.76 - 7.45
Dividend & Yield
N/A (N/A)
IBIO Stock Predictions, Articles, and Ibio Inc News
Hold iBio Shares as Q2 Highlights Strong Product Catalog
With iBio making key executive-level appointments and recording excellent fiscal stats, IBIO stock's value proposition is hard to ignore.
IBIO Stock: 5 Things for Investors to Know About iBio Today as Shares Zoom Higher
Ibio (IBIO) stock is on the rise Thursday despite a lack of news coming out today that would result in the movement today.
IBIO Stock Alert: Analyst Call Sends Shares of Pharma iBio Soaring
Shares of IBIO stock are taking off on Friday after an analyst from Cantor Fitzgerald initiated an Overweight rating and $3 price target.
Be Wary as iBio Seeks a Place in the Vaccine Game
IBIO stock remains volatile as the company continues its focus on a breakthrough product to combat the coronavirus pandemic.
A Lack of Progress Keeps IBIO Shares As a Sell
Investors bought the Covid-19 hype in IBIO stock. With little progress made, however, reality is setting in, which means the fade should continue.
Firming Financials Point to an Underappreciation of iBio Stock
The IBIO stock price is down, but that doesn't mean the company's in trouble. In fact, the data shows that iBio's fiscal health is improving.
Why iBio Remains Worth a Look In a Post-Pandemic Landscape
While its shot at pioneering a novel coronavirus vaccine has passed, iBio and its IBIO stock could benefit from other medical breakthroughs.
Biotech Innovator IBIO Is Down, but Not Out for the Long Term
Biotech innovator IBIO stock has been tossed around based on iBio’s COVID-19 vaccine progress, but its FastPharma tech is the long-term play.
iBio News: Why IBIO Stock Is Soaring 16% Today
Ibio (IBIO) is seeing shares of IBIO stock soar higher on Wednesday following news of a contract for the biotech company.
The Case for iBio Stock Is Real, but Leaves a Key Question Unanswered
iBio has a long-standing relationship with the United States defense industry. But that hasn't enough to give IBIO stock a leg up in the Covid-19 race.
It’s Time for iBio Speculators to Consider Something Else
One of the more intriguing high-risk, high-reward ideas in the Covid-19 space, IBIO stock had an opportunity to distinguish itself. But with the vaccine race heating up, the dangers outweigh the possibilities.
iBio Looks Well-Positioned to Succeed
iBio reports impressive Q1 results as biotech companies see a strong rally this year. Here’s the latest on IBIO stock.
Why iBio Presents a Dilemma to Shareholders
iBio’s first-quarter included steep losses and not much else. If IBIO stock is to rise to $2, investors need some good news to chew on.
Stay Away From iBio, Which Constantly Issues Shares to Survive
The latest in IBIO news: stay away from IBIO stock, which has over-issued shares to survive. The stock remains below the average issue price.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
C
